News
FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...
Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read ...
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a ...
The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.
The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...
9h
Axios on MSNVinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
With a demand that vaccine boosters be tested against placebos, RFK Jr. puts an old antivaccine claim at the forefront of government health policy.
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results